chrysin + irinotecan

Chrysin + irinotecan is an investigational combination therapy involving the natural flavonoid chrysin and the chemotherapeutic agent irinotecan. Chrysin is a bioactive compound found in honey and propolis, known for its anti-inflammatory, antioxidant, and potential anticancer properties. Irinotecan is a topoisomerase I inhibitor widely used in the treatment of colorectal cancer. The rationale for combining these agents centers on chrysin’s ability to induce intestinal UGT1A1 enzyme activity, which enhances glucuronidation of SN-38 (the active metabolite of irinotecan), thereby reducing gastrointestinal toxicity—specifically delayed diarrhea—without compromising antitumor efficacy. Preclinical studies suggest that this combination may have synergistic anti-tumor effects in colon cancer models[1][6][8]. Early clinical data indicate that co-administration is safe and may reduce the severity of chemotherapy-induced diarrhea[6].

Other names

CPT-11CPT11CPT 11